echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > The mRNA new crown vaccine has been approved for emergency use

    The mRNA new crown vaccine has been approved for emergency use

    • Last Update: 2021-03-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2 (Xinhua) -- The government has accepted the recommendation of the Medicines and Medical Products Regulatory Agency to approve the emergency use of Pfizer and BioNTech's new crown vaccine, a spokesman for the Ministry of Health and Social Health said on December 2, according to people's daily People's Daily Online. The vaccine will be available across the UK from next week.The UK has become the first country in the world to approve emergency use of the mRNA vaccine.The mRNA vaccinemRNA vaccine belongs to the nucleic acid vaccine. Nucleic acid vaccine refers to the particle carrier containing the encoded protein gene sequence, which is delivered to the host body by means of certain means, and expresses antigen protein through the host cell, thus inducing the body's immune response to the protein, and thus achieving the goal of preventing disease. As a new technology vaccine, nucleic acid vaccine is called the third generation of vaccine after the whole virus vaccine, recombinant sub-unit vaccine.The new coronavirus is a single-stranded RNA virus that is equivalent to mRNA in a cell and translates encoded proteins, such as shell proteins and the virus's RNA polymerase, directly within the cell. The new coronavirus vaccine, prepared using the nucleic acid vaccine technology route, can translate antigen proteins into the human body and induce the body to develop immunity.The advantage of mRNA vaccines is that the production process is simple and fast. Unlike inactivated vaccines, mRNA vaccines can be produced by simply copying viral nucleic acids, greatly simplifying the production process and making rapid vaccine production possible. However, the large-scale use of nucleic acid vaccine still faces many urgent technical problems. First, the antigen resistance of nucleic acid vaccine is low, which is related to the expression level of nucleic acid vaccine in the host cell;BioNTechBioNTech, Moderna and CureVac are currently among the world's top three mRNA therapists, with BioNTech and Moderna at the forefront of research and development of the new crown vaccine.Founded in 2008 and headquartered in Germany, BioNTech's cutting-edge products include personalized mRNA-based candidates, innovative chimed antigen-liked T-cells, new checkpoint immunomodulants, targeted cancer antibodies and small molecules.On November 18, Pfizer and BioNTech said the final results of Phase III clinical trials showed 170 confirmed cases out of 43,000 subjects, including 162 in the placebo group and only 8 in the experimental group, meaning BioNTech's mRNA vaccine was up to 95 percent effective. As a result of the news, Pfizer rose 3 percent and BioNTech jumped 10 percent.Modernafounded in 2010 and headquartered in Cambridge, Massachusetts. The company focuses on messenger RNA (mRNA) research and is committed to being a pioneer and leader in the discovery and development of mRNA drugs worldwide. At present, the company's research and development pipeline has a total of 21 vaccines and drugs, of which the new crown pneumonia (SARS-COV-2) vaccine is in clinical phase III. It's worth noting that 18 of the 21 drugs in the company's pipeline are mRNA drugs.On November 30th Moderna released final data on vaccine trials, with 196 patients in 30,000 subjects developing new coronary pneumonia, including 30 severe new crown patients. Of the 196 new crown patients, 185 were given a placebo and only 11 were vaccinated, which means that the vaccine is 94.1% effective in preventing new crown infections and 100% effective in severe cases. Although the final result is slightly lower than the 94.5 percent result in phase III, it is well above the FDA's 50 percent efficiency assessment requirement for a vaccine on the market.The comparison between thethat although both are mRNA vaccines, bioNTech's mRNA vaccine differs from Modena's mRNA vaccine.From the point of view of efficacy, the two sides do not know each other. BioNTech's mRNA vaccine is 95% efficient, and Moderna's mRNA vaccine is 94.1%.From the point of view of adverse reactions, the two sides are on the same level. Both sides say there are no serious adverse reactions, but given that the mRNA vaccine is a new technology, further observation is needed in phase IV clinical trials in the future. From the point of view of storage temperature, the Moderna vaccine wins. BioNTech and Pfizer's vaccines are extremely demanding for storage temperatures and need to be stored at -70 degrees C, and Moderna's mRNA vaccine can be stored for six months in an environment of minus 20 degrees C, one month in a normal refrigerator at 2-8 degrees C, and 12 hours at room temperature, greatly enhancing the universality of the vaccine. Considering that the price per ultra-low-temperature refrigerator is usually $5,000-$15,000, this is not friendly to medical facilities in developing countries. In terms of price, bioNTech vaccine wins. BioNTech vaccines are currently priced at $19.50 per dose, which is cheaper than Moderna's $25 to $37 per dose. BioNTech vaccine wins in terms of capacity. BioNTech plans to supply 1.3 billion doses of vaccine worldwide by 2021, while Moderna expects to have a capacity of 5-1 billion doses by 2021.
    (
    Sina Pharmaceutical News
    )
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.